# A Multicenter Assessment of ALD403 in Chronic Migraine

> **NCT02275117** · PHASE2 · COMPLETED · sponsor: **Alder Biopharmaceuticals, Inc.** · enrollment: 665 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **BIOLOGICAL:** ALD403
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02275117
- **Lead sponsor:** Alder Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-11
- **Target enrollment:** 665 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02275117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02275117, "A Multicenter Assessment of ALD403 in Chronic Migraine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02275117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*